(Q38074206)

28 August 2017

0 references

1 reference

title

A systematic review of vinorelbine for the treatment of breast cancer (English)

1 reference

28 August 2017

Ying-Chun Xu

1

1 reference

28 August 2017

Hong-Xia Wang

2

1 reference

28 August 2017

Lei Tang

3

1 reference

28 August 2017

Yue Ma

4

1 reference

28 August 2017

Feng-Chun Zhang

5

1 reference

28 August 2017

publication date

16 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

19

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

180-188

1 reference

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial

28 August 2017

cites work

1 reference

A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.

21 January 2018

1 reference

Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer

21 January 2018

1 reference

Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies

21 January 2018

1 reference

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer

21 January 2018

1 reference

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data

21 January 2018

1 reference

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

21 January 2018

1 reference

Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment

21 January 2018

1 reference

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial

21 January 2018

1 reference

Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.

21 January 2018

1 reference

Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients

21 January 2018

1 reference

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

21 January 2018

1 reference

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

21 January 2018

1 reference

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

21 January 2018

1 reference

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

21 January 2018

1 reference

Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

21 January 2018

1 reference

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

21 January 2018

1 reference

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer

21 January 2018

1 reference

A review of vinorelbine in the treatment of breast cancer

21 January 2018

1 reference

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TBJ.12071

1 reference

28 August 2017

1 reference